Drug Database
AL

alendronate (Binosto / Steovess / EX101)

✓ Approved

Ahn-Gook Pharmaceutical · 小分子 · 小分子

什么是 alendronate?

alendronate 是一种小分子,由Ahn-Gook Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Binosto, Steovess, EX101
公司Ahn-Gook Pharmaceutical
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

alendronate 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved
Congenital, familial and genetic disordersHypertrophic cardiomyopathyPhase III
Musculoskeletal and connective tissue disordersOsteoarthritisPhase II

相关研究文献

PubMedJFMS open reports2026-11-18

Surgical management of bilateral atypical tibial fractures associated with long-term bisphosphonate therapy in a cat.

Wong Justin K W JKW, Colthurst Stephanie M M SMM

An 8-year-old, indoor, male neutered Oriental mixed-breed cat was presented with acute bilateral pelvic limb lameness without preceding trauma. The cat had received oral alendronate for 4.5 years for the management of feline idiopathic hypercalcaemia. Radiographs revealed bilateral, closed, comminuted proximal tibial and fibular fractures with cortical sclerosis. Staged bilateral open reduction and internal fixation were performed using orthogonal locking compression plates. Alendronate therapy was discontinued, and the cat remained normocalcaemic during 8 months of follow-up. Despite robust stabilisation, traumatic re-fracture of the right tibia occurred after inadequate confinement, necessitating revision fixation with longer implants and the addition of allogeneic demineralised bone matrix (DBM). Delayed union and marked callus formation were observed in the left tibia, consistent with suppressed bone remodelling secondary to chronic alendronate therapy. In contrast, the revised right tibial fracture, treated with adjunctive DBM, demonstrated faster progression of healing. Radiographic monitoring demonstrated osseous union without further complications or evidence of additional fractures, illustrating that favourable outcomes are achievable in cats with bilateral bisphosphonate (BP)-associated insufficiency fractures when appropriately managed. This report represents the second documented case of BP-associated fractures in a cat managed surgically with extensive follow-up. It is the first to describe bilateral tibial fracture repair and the use of adjunctive DBM for BP-associated fractures. It highlights that favourable outcomes are achievable in these cases through orthogonal plating combined with adjunctive DBM, and discontinued BP therapy to reduce future fracture risk. This report also supports serial radiographic monitoring, particularly within 5 years of treatment initiation.

PMID 43048118
阅读全文 →
PubMedEuropean journal of pharmacology2026-11-17

Catalpol Prevents Ovariectomy-Induced Bone Loss Through DUSP6-Mediated Suppression of SMAD2/NFATc1 Signaling and Osteoclast Differentiation.

Wang Yuchen Y, Wang Lining L, Yu Weizhong W, Zhu Wenke W et al.

Postmenopausal osteoporosis is characterized by estrogen deficiency-induced disruption of bone remodeling. Catalpol exerts bone-protective effects, but its direct molecular target and underlying mechanism remain incompletely understood. To determine whether catalpol attenuates ovariectomy (OVX)-induced bone loss through dual-specificity phosphatase 6 (DUSP6)/SMAD family member 2 (SMAD2)/nuclear factor of activated T cells cytoplasmic 1 (NFATc1) signaling and to evaluate its effects on osteogenic differentiation. OVX rats were treated with catalpol (5, 10, or 20 mg/kg) or alendronate for 12 weeks. Bone microarchitecture, bone remodeling, and osteoclast-related changes were assessed. In RAW264.7 cells, DUSP6 dependence was examined by knockdown and rescue experiments. Catalpol-DUSP6 interaction was evaluated by molecular docking, cellular thermal shift assay, and microscale thermophoresis (MST). Osteogenic differentiation was assessed in MC3T3-E1 cells. Catalpol improved trabecular microarchitecture, increased osteoblast-related histomorphometric parameters, and suppressed osteoclast formation in OVX rats. Catalpol increased DUSP6 expression and DUSP6-SMAD2 association, reduced SMAD2 phosphorylation, and inhibited NFATc1 nuclear accumulation. DUSP6 knockdown attenuated these effects, whereas DUSP6 restoration restored catalpol responsiveness. MST demonstrated direct catalpol binding to WT-DUSP6 (Kd = 3.617 μM), while mutation of predicted binding residues weakened the interaction (Kd = 48.12 μM). Catalpol also enhanced alkaline phosphatase-positive area, matrix mineralization, and osteogenic protein expression. Catalpol attenuates OVX-induced bone loss through DUSP6-mediated suppression of SMAD2/NFATc1-dependent osteoclastogenesis and additionally promotes osteogenic differentiation in vitro.

PMID 43044746
阅读全文 →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-11-16

Bacterial DnaK Promotes CHIP-Mediated GPX4 Degradation: A Bone-Targeted DNAzyme-Nanozyme Strategy for Repair of Infected Bone Defects.

Gao Le L, Xi Yang Y, Guo Zhe Z, Xiao Mingxuan M et al.

Staphylococcus aureus infection impairs bone repair, but how bacterial proteins disrupt osteogenic progenitors remains unclear. The bacterial chaperone DnaK promotes glutathione peroxidase 4 (GPX4) degradation in bone marrow mesenchymal stem cells (BMSCs), accompanied by lipid peroxidation, ferroptotic injury, and impaired osteogenic differentiation. GPX4 protein turnover increases without a change in Gpx4 mRNA abundance. A candidate E3-ligase screen identifies the C terminus of Hsc70-interacting protein (CHIP) as a mediator of this response. Catalytically inactive CHIP attenuates DnaK-associated K48-linked GPX4 ubiquitination, while CHIP knockdown preserves GPX4 and osteogenic proteins in primary BMSCs. To target bacterial DnaK and host oxidative injury, a bone-targeted deoxyribozyme (DNAzyme)-nanozyme platform (DMPA) combines a dnaK-targeting DNAzyme with manganese hexacyanoferrate, polydopamine, and alendronate. In infected cultures, DMPA reduces bacterial dnaK transcript and DnaK protein abundance and improves BMSC redox balance and matrix mineralization. In a mouse model of infected tibial defects, DMPA promotes bone regeneration. These findings link bacterial DnaK to host GPX4 degradation through CHIP and establish a bone-targeted DNAzyme-nanozyme strategy that combines bacterial DnaK suppression with redox regulation to promote repair of infected bone defects.

PMID 43035966
阅读全文 →
PubMedBMJ open2026-11-12

Fracture rate and determinants of fractures and bone loss in women with postmenopausal osteoporosis discontinuing alendronate treatment: protocol for the Alendronate Discontinuation Study (ALEXIS) - a multicentre, randomised controlled trial.

Gram Freja F, Langdahl Bente L BL, Gram Jeppe J, Søe Kent K et al.

PMID 43020496
阅读全文 →
PubMedFood chemistry2026-11-12

A ready-to-use multifunctional tablet for one-pot effervescence-driven derivatization and salting-out assisted liquid-liquid extraction of sulfonamides in bovine blood and milk.

Lv Mengyuan M, Ma Yixin Y, Xiao Le L, Chen Di D

A one-pot effervescence-driven derivatization and salting-out assisted liquid-liquid extraction (OPED-SALLE) strategy was developed for rapid determination of sulfonamides (SAs) in bovine-derived samples by HPLC-FLD. The method integrates pH regulation, in situ derivatization, extraction, and phase separation into a single step using a pre-fabricated multifunctional effervescent tablet, enabling a ready-to-use workflow. CO₂ generation upon tablet addition promotes rapid dispersion, enhances mass transfer, and facilitates simultaneous derivatization and extraction. The method showed good linearity (R2 ≥ 0.99), satisfactory accuracy (96.27-118.10%) and precision (RSD ≤ 5.58%), with LODs of 0.13-0.69 ng/mL. Application to fortified milk and bovine blood samples yielded relative errors of -12.53% to 13.49%. Compared with conventional methods, OPED-SALLE offers greater process integration, shorter processing time (~2.2 min), and improved operational simplicity, demonstrating strong potential for routine analysis of SAs in complex matrices.

PMID 43019723
阅读全文 →
PubMedJAMA network open2026-11-11

Bisphosphonates vs Denosumab After Low-Trauma Fractures.

Lin Mike M, Nguyen Huy H, Tran Thach S TS, Blank Robert D RD et al.

Patients are at high risk of refracture and death in the immediate period following low-trauma fracture, but comparative evidence for antiresorptive therapies is limited. To compare refracture and all-cause mortality between patients who initiated nitrogen-containing bisphosphonates (N-BPs) and denosumab therapy after fractures. This cohort study used sequential target trial emulation of monthly trials among treatment-naive adults 50 years or older through the 12 months after incident low-trauma fracture with a new-user, active-comparator design. Linked administrative health data from the population of New South Wales, Australia, was used. Women entered from January 1, 2011, to June 30, 2018, and men from January 1, 2014, to June 30, 2018, both with 3 years of follow-up. Data were analyzed from December 1, 2025, to May 31, 2026. N-BP (alendronate, risedronate or zoledronic acid) vs denosumab. Three-year all-cause mortality and refracture. Primary analyses estimated intention-to-treat (ITT) associations with inverse probability weighting. Secondary analyses included per-protocol and Fine-Gray competing-risk analyses. Hazard ratios (HRs) greater than 1.00 indicated higher risk with N-BP. The cohort included 15 099 participants (overall mean [SD] age, 77.2 [9.2] years), of whom 12 529 (83.0%) were women and 2570 (17.0%) were men (79.9 [8.4] years). All-cause mortality rates with N-BP vs denosumab were 48.1 vs 48.9 per 1000 person-years in women and 123.0 vs 116.4 per 1000 person-years in men, with no clear association in women (ITT HR, 0.98 [95% CI, 0.87-1.10]) or men (ITT HR, 1.09 [95% CI, 0.93-1.25]). Refracture rates were 52.7 vs 46.5 per 1000 person-years in women and 70.5 vs 58.8 per 1000 person-years in men. Initiation of N-BP therapy was associated with higher refracture risk in women (ITT HR, 1.14 [95% CI, 1.05-1.26]) and men (ITT HR, 1.21 [95% CI, 1.03-1.42]). Competing-risk estimates were similar; per-protocol estimates were higher in women (HR, 1.30 [95% CI, 1.09-1.55]) and men (HR, 1.48 [95% CI, 1.10-1.98]). Risks were strongest following nonhip-nonvertebral (NHNV) fractures in women (HR, 1.21 [95% CI, 1.06-1.38]) and men (HR, 1.54 [95% CI, 1.10-2.15]). In this cohort study emulating a target trial, initiation of N-BP and denosumab therapy was associated with similar mortality, whereas initiation of N-BP was associated with higher refracture risk, particularly after NHNV fractures.

PMID 43013305
阅读全文 →

注册免费账户还可查看另外 7000 篇文献

免费注册查看全部文献 →

了解更多alendronate